Evidence map›Paper›PMID 42128048›Full record

ArticleThe Journal of investigative dermatology2026

PARP1 as a biomarker for differentiating melanoma from benign melanocytic lesions.

Aditi Sahu, Melissa Gill, Aundree Hermawan, Anjali Shinde, Ucalene Harris, Stephen Dusza, Miguel Cordova, Christi Alessi-Fox, Salvador Gonzalez, Sheryl Roberts and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Aditi SahuDermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. Electronic address: aditisahu@gmail.com.
Melissa GillDepartment of Pathology, SUNY Downstate Health Sciences University, Brooklyn, New York, USA; Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Solna, Stockholm, Sweden; Faculty of Medicine and Health Sciences, University of Alcalá, Madrid, Spain.
Aundree HermawanDermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA; University of Texas Southwestern Medical School, Dallas, Texas, USA.
Anjali ShindeDermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA; Department of Radiation Oncology, Mass General Hospital, Boston, Massachusetts, USA.
Ucalene HarrisDermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Stephen DuszaDermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Miguel CordovaDermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Christi Alessi-FoxUniversity of Rochester Medical Center, Rochester, New York, USA.
Salvador GonzalezFaculty of Medicine and Health Sciences, University of Alcalá, Madrid, Spain.
Sheryl RobertsWayne State University, Detroit, Michigan, USA; Karmanos Cancer Institute, Detroit, Michigan, USA.
Thomas ReinerEvergreen Theragnostics, Springfield, New Jersey, USA.
Ashfaq MarghoobDermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Anthony RossiDermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Chih-Shan Jason ChenDermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Allan HalpernDermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Klaus J BusamDepartment of Pathology and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Pascale GuiteraMelanoma Institute Australia, The University of Sydney, Sydney, Australia; Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Sydney, Australia.
Manu JainDermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Milind RajadhyakshaDermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Confocal video-mosaicking microscopy to guide surgery of superficially spreading skin cancersR01CA240771 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAMPS, OCTAVIA IRMA, RAJADHYAKSHA, MILIND · 2019 to 2023
$3.4M
Simultaneous coaxial widefield imaging and reflectance confocal microscopy for improved diagnosis of skin cancers in vivoR01EB028752 · NIBIB · MONTANA STATE UNIVERSITY - BOZEMAN · PI CAMPS, OCTAVIA IRMA, DICKENSHEETS, DAVID LEE · 2020 to 2023
$2.4M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA240771NIBIB NIH HHS R01 EB028752
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Melanoma diagnosisMolecular imagingPARP1PARPi-FLPRAME

Identifiers

PMID42128048
PMCPMC13546027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.